Follow
Paolo Denti
Title
Cited by
Cited by
Year
Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests
C Cobelli, GM Toffolo, CD Man, M Campioni, P Denti, A Caumo, P Butler, ...
American Journal of Physiology-Endocrinology and Metabolism 293 (1), E1-E15, 2007
3942007
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampicin concentrations: dosing implications
E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ...
Antimicrobial agents and chemotherapy, AAC. 01833-10, 2011
163*2011
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines
H McIlleron, R Rustomjee, M Vahedi, T Mthiyane, P Denti, C Connolly, ...
Antimicrobial agents and chemotherapy 56 (6), 3232-3238, 2012
1212012
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
P Denti, K Jeremiah, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ...
PloS one 10 (10), e0141002, 2015
1072015
Characterizing multisegment foot kinematics during gait in diabetic foot patients
Z Sawacha, G Cristoferi, G Guarneri, S Corazza, G Donà, P Denti, ...
Journal of neuroengineering and rehabilitation 6, 37, 2009
972009
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection
KE Dooley, P Denti, N Martinson, S Cohn, F Mashabela, J Hoffmann, ...
The Journal of infectious diseases 211 (2), 197-205, 2015
952015
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction
MT Chirehwa, R Rustomjee, T Mthiyane, P Onyebujoh, P Smith, ...
Antimicrobial agents and chemotherapy 60 (1), 487-494, 2016
782016
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ...
Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014
762014
A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs
A Daskapan, LR Idrus, MJ Postma, B Wilffert, JGW Kosterink, Y Stienstra, ...
Clinical pharmacokinetics 58 (6), 747-766, 2019
652019
Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV
K Jeremiah, P Denti, E Chigutsa, D Faurholt-Jepsen, G PrayGod, ...
Antimicrobial agents and chemotherapy 58 (6), 3468-3474, 2014
652014
UCT943, a next-generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria
C Brunschwig, N Lawrence, D Taylor, E Abay, M Njoroge, GS Basarab, ...
Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 00012-18, 2018
622018
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients
SP Zvada, P Denti, FA Sirgel, E Chigutsa, M Hatherill, S Charalambous, ...
Antimicrobial agents and chemotherapy 58 (1), 503-510, 2014
562014
Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs
MGG Sturkenboom, AG Märtson, EM Svensson, DJ Sloan, KE Dooley, ...
Clinical pharmacokinetics 60 (6), 685-710, 2021
542021
Delayed sputum culture conversion in TB-HIV co-infected patients with low isoniazid and rifampicin concentrations
C Sekaggya-Wiltshire, A von Braun, M Lamorde, B Ledergerber, ...
Clinical Infectious Diseases, 2018
54*2018
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB
A Naidoo, M Chirehwa, H McIlleron, K Naidoo, S Essack, N Yende-Zuma, ...
Journal of Antimicrobial Chemotherapy 72 (5), 1441-1449, 2017
532017
Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis
N Rockwood, JG Pasipanodya, P Denti, F Sirgel, M Lesosky, T Gumbo, ...
Clinical Infectious Diseases 64 (10), 1350-1359, 2017
522017
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in …
K Singh, J Okombo, C Brunschwig, F Ndubi, L Barnard, C Wilkinson, ...
Journal of medicinal chemistry 60 (4), 1432-1448, 2017
512017
Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis
P Denti, AJ Garcia-Prats, HR Draper, L Wiesner, J Winckler, S Thee, ...
Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 01521-17, 2018
492018
Clinical standards for the dosing and management of TB drugs
JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ...
The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022
462022
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture
E Chigutsa, K Patel, P Denti, M Visser, G Maartens, CMJ Kirkpatrick, ...
Antimicrobial agents and chemotherapy 57 (2), 789-795, 2013
452013
The system can't perform the operation now. Try again later.
Articles 1–20